About The Study: The finding of a slightly lower prevalence of any adenoma in the younger compared with the older age group (35.4% vs 40.8%) in the current study is consistent with an evaluation of 2001 screening colonoscopies from a university-based medical center between 2019 and 2021, which reported slightly lower rates of adenoma detection in those ages 45 to 49 vs 50 to 54 (34.3% vs 38.2%) and with a large study of adenoma detection rates in those ages 45 to 49 vs 50 to 54 (28.6% vs 31.8%) who underwent a screening colonoscopy before the change in guidelines (i.e., 2014-2020). 

A UCLA-led study found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial cancer, but also improves the quality of that extended survival by minimizing the time spent suffering from disease symptoms or severe treatment side effects.

A new study from researchers at Fox Chase Cancer Center released at the American Society of Clinical Oncology’s (ASCO) Annual Meeting demonstrates that a simple addition to the electronic medical record (EMR) system can assist fertility preservation efforts for young adult cancer patients.

In a randomized clinical trial, Mass General Brigham researchers and their colleagues found that combining inavolisib with the standard two-drug treatment resulted in longer patient survival and slower cancer progression for those with the PIK3CA gene mutation.

 

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today  show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments. Importantly, the phase 3 trial’s rapid development and implementation, coupled with its successful enrollment of a group of patients broadly representative of the larger U.S. population, establish Pragmatica-Lung as a paradigm-shifting model for the design and conduct of future large randomized studies.